Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Artesunate is an artemisinin derivative from Artemisia annua and is being applied as a first-line drug for malaria treatment. In addition to anti-malarial effects, anti-cancer, anti-viral, and anti-inflammatory activities have been reported for artemisinin derivatives. In this study, we investigated the effects of artesunate on naïve T cell activation and Th1/Th2 differentiation. Artesunate inhibited the proliferation of CD4(+) T cells and the production of IL-2, T cell growth factor. Moreover, artesunate reduced the expression of cell surface protein CD25 (IL-2 receptor alpha chain) and CD69 on CD4(+) T cells. Artesunate showed inhibitory effects on naïve T cell activation but artesunate increased the production of IFN-γ and IL-4 under Th1 and Th2 skewed condition respectively. Therefore, these results suggest that artesunate has a negative mitogenic effect on CD4(+) T cells but reinforces the function of effector T cells.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12272-014-0491-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ADAM9 Promotes Glycolysis in Th17 Cells and Autoimmunity Through Activation of IGF-1 Signaling.
Arthritis Rheumatol
July 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Objective: Interleukin-17-producing CD4 Th17 cells contribute to the pathogenesis of autoimmune diseases, including crescentic glomerulonephritis. Although ADAM9 has been reported to contribute to organ inflammation, the mechanism remains poorly understood. The goal of the current study was to investigate how ADAM9 alters T cell metabolism to promote the generation of Th17 cell differentiation.
View Article and Find Full Text PDFT follicular helper cells (T): From physiological to pathological aging.
Eur J Intern Med
September 2025
Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy; Istituti Clinici Scientifici ICS Maugeri - S.p.A.-Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Scientifico di Telese Terme, Telese, Italy. Electronic address:
The fraction that the elderly represent in the world's population is growing rapidly; numerous alterations that impact all organs and systems, including the immune system, are related to aging. A complex process common in the elderly, known as immunosenescence, is characterized by a decreased ability to respond to vaccination as well as an increased risk of bacterial and viral infections, autoimmune, cardiovascular and neurodegenerative diseases. These processes are associated with alterations in the innate and adaptive immune system and lead to a condition of chronic low-grade inflammation, referred to as inflammaging.
View Article and Find Full Text PDFA 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial.
Lancet Infect Dis
September 2025
The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Background: Based on results from preclinical and clinical studies, a five-drug combination of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine was identified with treatment shortening potential for drug-susceptible tuberculosis; the Clo-Fast trial aimed to determine the efficacy and safety of this regimen. We compared 3 months of isoniazid, rifapentine, pyrazinamide, ethambutol, and clofazimine, administered with a clofazimine loading dose, to the standard 6 month regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol in drug-susceptible tuberculosis.
Methods: Clo-Fast was a phase 2c open-label trial recruiting participants at six sites in five countries.
Epstein-Barr virus and cytomegalovirus co-infections and mortality risk in patients with HIV-associated cryptococcal meningitis: a post-hoc analysis of a prospective nested cohort in the AMBITION-cm randomised controlled trial.
Lancet HIV
September 2025
Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, UK; Botswana Harvard Health Partnership, Gaborone, Botswana.
Background: HIV-associated cryptococcal meningitis case fatality remains greater than 25%. Co-prevalent infections might contribute to poor outcomes. We aimed to ascertain the prevalence and the clinical significance of Epstein-Barr virus (EBV) and cytomegalovirus co-infections in patients with cryptococcal meningitis to guide potential therapeutic interventions.
View Article and Find Full Text PDFDeciphering pancreatobiliary intraductal oncocytic papillary neoplasms: integrative analysis of histomorphologic patterns, immunophenotypic markers, and emerging molecular biomarkers.
World J Surg Oncol
September 2025
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan Dongcheng District, Beijing, 100730, China.
Purpose: We reviewed recent advancements in the characterization of intraductal oncocytic papillary neoplasm (IOPN) of the pancreas, with a specific focus on developments in immunohistochemical markers, molecular pathology, and pathogenic mechanisms over the past ten years (2015-2024). Through comprehensive analysis of current literature, we aimed to elucidate the evolving understanding of IOPN's biological behavior and diagnostic features, while identifying potential areas for future research in this distinctive pancreatic neoplasm.
Methods: English-language articles on IOPN were searched from Pubmed from the first report of IOPN of the pancreas in 2015 to 2024.